Kornimate/medical-research-clean huggingface dataset:
cancer panel from blood of lung cancer patients

Conditions: Non Small Cell Lung Cancer Metastatic; Non Small Cell Lung Cancer Recurrent

Summary: molecular profiling of lung cancers using circulating tumor dna (ctdna) in the blood of patients is rapidly becoming established as a useful source of information to aid clinical decision-making. this study is aimed to to compare concordance rate between tissue based cancer panel analysis and blood based cancer panel analysis in lung cancer patients (both by ngs technique).

this study is comprised of two cohorts as below: cohort a: inoperable, untreated, non-small cell lung cancer patients cohort b: non-small cell lung cancer patients who are in the treatment with targeted agents including immune checkpoint inhibitors

Eligibility criteria:
inclusion criteria: * provision of informed consent prior to any study specific procedures, sampling, and analyses * pathologically confirmed non-small cell lung cancer * male or female, aged at least 20 years * matches one of two criteria : 1. cohort a: patients who are diagnosed with metastatic/recurrent non-small cell lung cancer and planned to receive first line chemotherapy 2. cohort b: patients with recurrent/metastatic non-small cell lung cancer who have been receiving molecular targeted therapy, including immune checkpoint inhibitor, and have tumor shrinkage with the agent. exclusion criteria: * any concurrent and/or other active malignancy that has required treatment within 3 years * patients with mixed small cell histology * life expectancy less than 3 months * insufficient tissue for ngs test

Keywords: nsclc cancer panel ngs actionable mutation immune checkpoint inhibitor
clinical study of the cardiofocus endoscopic ablation system for the treatment of symptomatic af

Conditions: Paroxysmal Atrial Fibrillation

Summary: the purpose of this study is to determine the safety and effectiveness of the endoscopic ablation system - adaptive contact (eas-ac) in treated paroxysmal atrial fibrillation (paf) with pulmonary vein isolation (pvi).


Eligibility criteria:
inclusion criteria: * symptomatic, paroxysmal atrial fibrillation (af) * 18 to 70 years of age * failure of at least one aad * others exclusion criteria: * generally good overall health as determined by multiple criteria * willing to participate in a study * others

Keywords: treatment of paf using eas-ac
knowledge, attitude, and practice in a group of egyptian dentists towards preventive measures in pediatric dentistry: a cross-sectional study

Conditions: Dental Caries

Summary: the study will include general dental practitioners or dental specialists from police academy hospital and pediatric dentists from pediatric dentistry department at faculty of dentistry cairo university. a self-administered questionnaire will be given to dentists by direct interviewing and they will be allowed to complete the questionnaire in faculty of dentistry, cairo university or police academy hospital. the data will be based on a collection of responses to the 38 items in the questionnaire.


Eligibility criteria:
inclusion criteria: * egyptian dentists working in either faculty of dentistry cairo university or police academy hospital. * postgraduate students. exclusion criteria: * refusal to participate in the study
study using citrate to replace heparin in babies requiring extracorporeal membrane oxygenation (ecmo)

Conditions: Heart Defects, Congenital; Respiratory Insufficiency

Summary: the purpose of this study is to determine the safety and efficacy of citrate to provide anticoagulation of an ecmo circuit without patient anticoagulation. the standard method of providing ecmo circuit anticoagulation is the use of heparin which also anticoagulates the patient and increases the risk of patient bleeding.

extracorporeal membrane oxygenation (ecmo) is a form of extended heart/lung bypass support that has been used to treat more than 650 patients over 20 years at vanderbilt. over 29,000 patients have been treated worldwide. bleeding is the most common complication during ecmo because of systemic anticoagulation with heparin. it is most commonly seen in patients following surgery either preceding or while on ecmo support. regional citrate anticoagulation for hemodialysis was first introduced in 1961. it is the ideal alternative to heparin in patients who are at increased risk for bleeding. it permits effective anticoagulation across the extracorporeal circuit without impacting the patient's systemic coagulation. citrate functions by binding free calcium, thereby inhibiting coagulation in both the intrinsic and extrinsic coagulation pathways. the purpose of this study is to evaluate the use of citrate as a regional anticoagulant in the ecmo circuit in high risk infants less than one year of age.

Eligibility criteria:
inclusion criteria: * infant less than one year of age and less than 6 kg * informed consent obtained from parent * one or more of the following diagnoses: * post-op congenital heart surgery * congenital diaphragmatic hernia * sepsis with coagulopathy not corrected prior to ecmo * other newborn diagnosis with grade i or ii ivh * infant requires/is on ecmo exclusion criteria: * consent denied or unobtainable * age greater than one year * weight greater than 6 kg * gestational age less than 34 weeks

Keywords: heart defects, congenital extracorporeal membrane oxygenation citric acid heparin respiratory insufficiency
quantitative mri of bone marrow in patients with acute lymphoblastic leukemia

Conditions: Acute Leukemia

Summary: the study is aimed at assessing changes in the bone marrow of patients from 6 to 18 years old with a diagnosis of acute lymphoblastic leukemia during chemotherapy. patients of the same age without hematological diseases will be recruited as a control group.

the ratio of fat to water in the bone marrow depends on the cellularity of the bone marrow. in addition to the water/fat ratio in bone marrow there are also other parameters for quantitative mri assessment. these include the apparent diffusion coefficient (acd), the t1 relaxation time, mapping of the macromolecular proton fraction. the undoubted advantage of mri is its non-invasiveness and the ability to assess any localization of the bone marrow. mri may become a new non-invasive method for assessing the ratio of fat to cells in the bone marrow in children with hematological malignancies, which can help in making a diagnosis and monitoring the response to therapy.

Eligibility criteria:
inclusion criteria: 1. patients from 6 to 18 years old 2. diagnosis of acute lymphoblastic leukemia during chemotherapy 3. patients of the same age without hematological diseases exclusion criteria: 1. patients less then 6, and older then 18 years old 2. patients who cannot perform the study mri without general anesthesia

Keywords: quantitative mri acute lymphoblastic leukemia bone marrow children
ultrasound-guided 5% dextrose injection for carpal tunnel syndrome

Conditions: Carpal Tunnel Syndrome

Summary: this study was a prospective randomized double-blind clinical trial conducted at the physical medicine and rehabilitation clinic of a local research and training hospital in turkey from october 2023 and may 2024. patients diagnosed with cts were classified into three groups: severe, mild, and moderate cts, based on the results of electrophysiological tests. an ultrasound-guided 5% dextrose in water injection was performed. the primary outcome measurement was the visual analog scale (vas), while secondary measurements were the boston carpal tunnel syndrome questionnaire (bctq) and the dolour neuropathic en 4 questions (dn4) questionnaire. the measurements were performed before the injection and at the first week, first month and third month follow-up times. the distribution of data within groups was examined using the shapiro-wilk test and q-q plots. the study also analyzed temporal changes, group differences, and intergroup changes using repeated measures anova models.


Eligibility criteria:
inclusion criteria: 1. paresthesia/dysesthesia, painful swelling with clumsy weakness of the hand exacerbated by sleep or repetitive use of the wrist, and relieved by shaking the hand with postural change. 2. sensory loss with numbness in the median nerve-innervated regions of the hand. 3. weakness with atrophy of the median nerve-innervated thenar muscles. 4. positive phalen's test and/or tinel's sign. 5. the diagnosis should be confirmed with electrodiagnostic studies. exclusion criteria: 1. history of cervical myelomalacia, polyneuropathy, brachial plexopathy, or thoracic outlet syndrome. 2. history of systematic infection, and rheumatologic disorders. 3. previous steroid injection for carpal tunnel syndrome.

Keywords: dextrose carpal tunnel syndrome ultrasound
effect of smart watch and app on pap adherence in osa (watch-osa)

Conditions: Obstructive Sleep Apnea of Adult; Positive Airway Pressure; Adherence, Treatment; Smart Watch

Summary: continuous positive airway pressure (cpap) is highly effective in treating obstructive sleep apnea (osa). however, this treatment modality relies heavily on patient adherence, and poor adherence to the treatment limits its effectiveness in treating osa. strategies to augment adherence are needed in the management of osa. the smart watch and linked app provide various health information, including sleep, snoring or oxygen saturation during sleep, exercise, blood pressure, and electrocardiogram. the smart watch and linked app could potentially improve adherence to positive airway pressure (pap) treatment. this randomized controlled trial (rct) aimed to examine whether the use of smart watch and app can increase pap adherence in patients with osa.


Eligibility criteria:
inclusion criteria: * diagnosed with osa (apnea-hyponea index \[ahi\])≥ 5 /h) by type 1 polysomnography * no prior use of pap (cpap or auto-adjusting pap \[apap\]), or no prior use of pap within the previous 90 days in patients who had received pap therapy, or current pap users with average daily usage (all days) \< 4 hours within the previous 90 days exclusion criteria: * patients who refuse pap therapy * patients who have used a smart watch (e.g., galaxy watch, apple watch, etc.) within the previous 90 days * patients with central sleep apnea or neuromuscular disease * patients receiving supplemental oxygen therapy due to underlying diseases including heart failure, stroke, chronic obstructive pulmonary disease, interstitial pulmonary disease, hypoventilation syndrome, or whose baseline oxygen saturation is less than 90% * patients with implanted cardiac pacemakers, defibrillators, or other electronic devices * patients who are inexperienced in using smartphones, apps, or smart watches * patients with an inability or unwillingness to provide informed consent
preemie tots: a pilot study to understand the effects of prematurity in toddlerhood

Conditions: Preterm Birth; Child Development; Child Behavior

Summary: the purpose of this study is to examine whether supplementation with certain polyunsaturated fatty acids can help development and behavior of children born preterm.


Eligibility criteria:
inclusion criteria: 1. child born at less than or equal to 29 completed weeks' gestation; 2. child between 18 months, 0 days and 38 months, 30 days old chronological age; 3. child admitted to nicu and/or had a neonatology clinic follow up visit scheduled. 4. child showing some autistic symptoms; 5. child between the 5th and 95th percentiles (per who growth chart) for weight at his/her most recent hospital visit; 6. english spoken in the home, demonstrate ability to communicate in english well-enough to understand study, informed consent, and study questionnaires; and 7. have informed consent on file. exclusion criteria: 1. consume lcpufa supplement drops, chews, powders, pediasure, or fatty fish more than 2x per week; 2. unable to tolerate venipuncture; 3. any major malformation that would preclude participation; 4. cerebral palsy (quadriparesis only); 5. deafness; 6. blindness; 7. bleeding disorder; 8. type i diabetes; 9. fragile x syndrome, rett syndrome, angelman syndrome, tuberous sclerosis; 10. non febrile seizure in the last month without a clear and resolved etiology; 11. feeding problem that may inhibit full participation; 12. known fish allergy; 13. known canola/rapeseed allergy or sensitivity; or 14. recorded score of \<70 on bayley cognitive section within the past year.
mechanisms of low levels of apolipoprotein b

Conditions: Cardiovascular Diseases; Heart Diseases; Hypobetalipoproteinemia

Summary: to determine mechanisms of low levels of apolipoprotein b.

background: elevated apob levels are associated with an increased risk of coronary heart disease. hypobetalipoproteinemia (hblp) is characterized by apob levels less than the 5 percentile. dr. welty, the principal investigator, sequenced mutations for truncated forms of apob-67, apob-55 and apob-44.4 which causes hblp, described a kindred from the framingham heart study with hblp due to an unidentified apob gene mutation and purified apob-67 containing lipoprotein particles. heterozygous apob-67 subjects have one normal allele making apob-100; therefore, apob levels would be predicted to be at least 50 percent of normal; however, they are 24 percent of normal. dr. welty has shown that these lower than expected levels result from decreased production of vldl apob-100, ldl apob-100 and apob-67, increased catabolism of vldl apob-100, and increased direct removal of apob-67 from vldl. design narrative: the first aim is to locate the apob gene mutation in the framingham kindred. the second aim is to perform stable isotope studies in the apob-55 and apob-44.4 kindreds to determine if apob metabolism for these shorter truncations is similar to that for apob-67. in aim three, apob-100 synthesis is studied in heterozygous apob-70 transgenic mice. if it is 25-25 percent of normal litter mates, the mechanism for this reduction in apob-100 levels will be studied in hepatocytes isolated from the transgenic mice. in specific aim 4, size and composition of vldl are compared in apob-67 subjects and controls to determine if larger size or compositional changes account for the faster catabolism of vldl apob-100. the study has been extended through june 2007.

Eligibility criteria:
no eligibility criteria
deep brain stimulation effects study

Conditions: Parkinson's Disease

Summary: the purpose of this study is to provide proof-of-concept that the test product can perform as intended in an intra-operative setting and the responses to the test product are perceivable in a person. the study will also compare results of the test product to the commercially-available product. hypothesis: the test product will elicit successful test results in over 90% of test product.


Eligibility criteria:
inclusion criteria: * subject is indicated for activa® dbs implant for the treatment of parkinson's disease and scheduled for surgery at the study site. * subject is willing to sign the informed consent to participate in the study. * subject is 18 years of age or older. * subject is a male or non-pregnant female. * subject has no factors that would put the subject at an additional risk for intra-operative or postoperative bleeding. this includes underlying disorders of the coagulation cascade (eg, hemophilia), disorders that affect platelet count or function (eg, von willebrand's disease), as well as administration of any anti-platelet or anti-coagulant medication in the 7 days prior to surgery, or any history of anticoagulant or aspirin use, that in the view of the neurosurgeon or neurologist would place the subject at an increased risk for intra-operative or postoperative bleeding. exclusion criteria: * subject is indicated for dbs for treating a disorder other than parkinson's disease. * subject has any medical contraindications to undergoing dbs surgery, (eg, infection, coagulopathy, or significant cardiac or other medical risk factors for surgery). * subject has a history of hemorrhagic stroke. * subject has a history of a neurosurgical ablation procedure. * subject is currently enrolled in or plans to enroll in any concurrent study that may confound the results of this study, as determined by the investigator or medtronic. * subject has a diagnosis of acute myocardial infarction or cardiac arrest less than or equal to 6 months prior to the screening testing. * subject has a history of a seizure disorder * subject requires short surgery time due to general health issues, as determined by the investigator. * subject is a woman who is pregnant or planning to become pregnant, or a woman of child-bearing potential, who is not using a medically-acceptable method of birth control. women of child-bearing potential must undergo a pregnancy test, with a clear negative result, no more than 7 days prior to the investigational procedure visit.
small particle steroids in refractory asthma

Conditions: Asthma

Summary: the purpose of this study is to determine whether an inhaled steroid with a small particle size can be an additional treatment option in patients with refractory eosinophilic asthma.

we have identified a group of patients with refractory asthma who have ongoing eosinophilic airway inflammation despite high dose inhaled corticosteroids. traditional inhaled steroids have a relatively proximal airway distribution which may lead to inadequate treatment of the distal airways. we aim to demonstrate that a steroid inhaler with a smaller particle size which targets the distal airways can be a useful additional treatment option in this group of patients.

Eligibility criteria:
inclusion criteria: * age 18-80 * acq \>1.5 or a requirement for oral steroids twice a year or more * high dose inhaled steroid (\>1000mcg bdp or equivalent) * treatment with or unsuccessful trial of: * long-acting beta agonist * leukotriene antagonist * sputum eosinophil count \>3% despite high dose inhaled steroid or \>2% with serum eosinophils \>0.4x10exp9/l * clinical response to 2 weeks of oral prednisolone: (any one) * reduction in acq by 0.5 or more * increase in fev1 by 200ml * normalisation of exhaled nitric oxide or reduction of \>25ppb exclusion criteria: * current smoker, or ex-smoker for \<12 months * current treatment with an extrafine steroid inhaler * respiratory infection within the last 4 weeks * pregnancy or lactation * poor compliance with usual asthma medication * clinical diagnosis of significant bronchiectasis * use of a medication which may interact with ciclesonide: * ketoconazole or itraconazole * ritonavir, nelfinavir

Keywords: ciclesonide asthma therapeutic uses pulmonary eosinophilia nitric oxide lung diseases respiratory tract diseases
99mtc-abh2 spect/ct in breast cancer

Conditions: Breast Cancer

Summary: this prospective study will investigate the potential usefulness of 99mtc-abh2 spect/ct in the diagnostic performance and evaluation efficacy of breast cancer.

this study aims to assess the diagnostic performance of 99mtc-abh2 spect/ct for the detection of her2-positive primary breast cancer and possible metastases. visual and semiquantitative methods will be utilized to evaluate the acquired spect/ct images. a comparative analysis of tumor imaging data and her2 expression obtained by immunohistochemistry (ihc) and/or fluorescent in situ hybridization (fish) analysis of biopsy samples will further be conducted. results of her2 expression imaging may have potential significance in screening and monitoring individuals for targeted therapy with monoclonal antibodies, like trastuzumab.

Eligibility criteria:
inclusion criteria: * clinically suspected primary breast cancer by mammography or ultrasonography and being able to sign the written informed consent form exclusion criteria: * pregnancy or lactation, impaired liver or kidney failure, and undergoing any preceding local or systemic therapies that might interfere her2 binding
prophylactic mesh in cytoreductive surgery

Conditions: Incisional Hernia

Summary: evaluate the effectiveness of mesh reinforcement in high-risk patients to prevent incisional hernia.

based on the hypothesis that oncological cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy (hipec) is associated with an increased risk of developing incisional hernia in the postoperative period, with an expected incidence of 50% at 24 months, we designed a prospective, multicenter and randomized clinical study to demonstrate the utility of the meshes in the prevention of incisional hernia, hoping to reduce the incidence to 15% at 24 months.

Eligibility criteria:
inclusion criteria: * completeness of cytoreduction after surgery (cc-score) cc-0, cc-1 exclusion criteria: * completeness of cytoreduction after surgery (cc-score) cc-2, cc-3

Keywords: hyperthermic intraperitoneal chemotherapy cytoreduction surgery prophylactic mesh
ro 31-7453 in treating patients with metastatic solid tumors

Conditions: Unspecified Adult Solid Tumor, Protocol Specific

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. purpose: randomized phase i trial to determine if ro 31-7453 is more effective with or without food in treating patients who have metastatic solid tumors.

objectives: i. assess the impact of food on the bioavailability of ro 31-7453 in patients with locally advanced or metastatic solid tumors. outline: this is a randomized, crossover study. patients are randomized to one of two treatment arms. arm i: patients receive oral ro 31-7453 under fasting conditions on day 1. after a 1-week washout period, patients receive oral ro 31-7453 under fed conditions. arm ii: patients receive fed treatment as in arm i on day 1. after a 1-week washout period, patients receive fasted treatment as in arm i. both arms: at the start of week 3, patients may continue to receive oral ro 31-7453 every 12 hours on days 1-4. treatment repeats every 3 weeks for at least 24 weeks in the absence of disease progression or unacceptable toxicity. patients are followed at 7 days. projected accrual: a total of 10 patients (5 per arm) will be accrued for this study.

Eligibility criteria:
disease characteristics: histologically or cytologically confirmed locally advanced or metastatic solid tumor for which no standard therapy is available no cns metastases patient characteristics: age: 18 and over performance status: karnofsky 60-100% life expectancy: not specified hematopoietic: hemoglobin at least 9 g/dl wbc at least 3,000/mm3 absolute neutrophil count at least 1,500/mm3 platelet count at least 100,000/mm3 hepatic: bilirubin no greater than 1.5 times upper limit of normal (uln) ast and alt no greater than 1.5 times uln (4 times uln for liver metastases) alkaline phosphatase no greater than 2.5 times uln (4 times uln for liver or bone metastases) renal: creatinine no greater than 1.5 times uln cardiovascular: no history or clinical signs of significant cardiovascular disease other: no other serious concurrent illness no greater than grade ii neuropathy no evidence of gastrointestinal dysfunction no intolerance to a high-fat meal not pregnant or nursing negative pregnancy test fertile patients must use effective contraception prior concurrent therapy: biologic therapy: at least 3 weeks since prior biologic therapy chemotherapy: at least 4 weeks since prior chemotherapy (6 weeks for mitomycin or nitrosoureas) endocrine therapy: at least 2 weeks since prior endocrine therapy (except for antiandrogen therapy) concurrent antiandrogen therapy allowed concurrent corticosteroids allowed if stable dose for at least 2 weeks prior to study radiotherapy: at least 3 weeks since prior radiotherapy surgery: not specified other: no prior enrollment in this study at least 4 weeks since prior investigational drugs no other concurrent investigational agents

Keywords: unspecified adult solid tumor, protocol specific